Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Remission Evaluation of a Metabolic Intervention for Type 2 Diabetes With IGlarLixi

Trial Profile

Remission Evaluation of a Metabolic Intervention for Type 2 Diabetes With IGlarLixi

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 20 Oct 2023

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Insulin-glargine/lixisenatide (Primary) ; Insulin glargine; Metformin
  • Indications Type 2 diabetes mellitus
  • Focus Therapeutic Use
  • Acronyms REMIT-iGL
  • Most Recent Events

    • 20 Oct 2023 Results examining whether remission can be achieved by combining lifestyle approaches and short-term intensive glucose-lowering therapy, published in the Diabetes, Obesity and Metabolism
    • 29 Jun 2021 Primary endpoint (The first occurrence of diabetes relapse) has been met, as per results presented at the 81st Annual Scientific Sessions of the American Diabetes Association.
    • 29 Jun 2021 Results (n=160) assessing induction of diabetes remission following a short-term treatment with insulin glargine, lixisenatide and metformin and changes in exercise and dietary behaviours, presented at the 81st Annual Scientific Sessions of the American Diabetes Association.
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top